Related Experiment Video
Updated: Sep 14, 2025
07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.5K
The Sting Challenge Test Shows High Negative Predictive Value in Patients Receiving Venom Immunotherapy
T Alfaya Arias1, A Vega Castro2,3, D Garnica-Velandia4,5
1Allergy Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Summary
The sting challenge test (SCT) accurately predicts venom immunotherapy (VIT) effectiveness, showing a high negative predictive value. This test is safe and useful for assessing if VIT has worked for patients with Hymenoptera allergies.
Area of Science:
- Allergy and Immunology
- Clinical Trials
- Toxicology
Background:
- The sting challenge test (SCT) is the gold standard for evaluating venom immunotherapy (VIT) efficacy.
- However, its precise predictive value in real-world clinical settings remains under investigation.
Purpose of the Study:
- To evaluate the predictive value of the SCT in patients undergoing VIT.
- To assess the safety and utility of SCT for determining VIT effectiveness.
Main Methods:
- A multicenter retrospective observational study included 261 patients receiving VIT.
- Data collected included patient demographics, diagnosis, immunotherapy details, SCT outcomes, and subsequent field sting events.
- SCTs were performed using various Hymenoptera venoms, with results and field sting data analyzed.
Main Results:
- The study analyzed 372 SCTs and 306 subsequent field stings across 261 patients.
- The SCT demonstrated a high negative predictive value (NPV) of 94.9% for predicting negative field stings.
- The positive predictive value (PPV) for the SCT was 33.3%, indicating limitations in predicting positive field stings.
Conclusions:
- The sting challenge test (SCT) is a safe procedure for patients undergoing venom immunotherapy.
- The high NPV of the SCT strongly supports its utility in assessing the effectiveness of VIT.
- The SCT is a valuable tool for clinicians managing patients with Hymenoptera venom allergies.
